Compositions and methods that inhibit il-23 signaling
US-2024425579-A1 · Dec 26, 2024 · US
Heparanase splice variant
US9428586B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9428586-B2 |
| Application number | US-201013512921-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 30, 2010 |
| Priority date | Dec 1, 2009 |
| Publication date | Aug 30, 2016 |
| Grant date | Aug 30, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A monoclonal or polyclonal antibody comprising an antigen binding site that binds specifically to T5, with SEQ ID NO: 1, polypeptide, wherein said antibody binds to the known, wild type heparanase protein with a binding affinity that is at least 5 times lower than a binding affinity to T5, with SEQ ID NO: 1, wherein the antibody is secreted by 9c9 hybridoma deposited according to the provisions of the Budapest Treaty with the Health Protection Agency Culture Collections (Centre for Emergency Preparedness & Response, Porton Down, Salisbury SP4 OJG, United Kingdom), having a Accession Number: 10111101. 2. A pharmaceutical composition, comprising the antibody of claim 1 , and a pharmaceutically acceptable carrier. 3. A method of treating a subject suffering from a disorder characterized by the presence of tumor cells expressing T5, by administering to the subject a therapeutically effective amount of the antibody of claim 1 .
Assignees
Inventors
Classifications
catalytic nucleic acids, e.g. ribozymes · CPC title
Antisense · CPC title
interfering nucleic acids [NA] · CPC title
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
- C07K16/30Primary
from tumour cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9428586B2 cover?
- The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof.
- Who is the assignee on this patent?
- Shemesh Ronen, Ayalon-Soffer Michal, Levine Zurit, and 8 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/30. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).